

## Datasheet: 9801-8006

<b>Description:</b>	MOUSE ANTI YELLOW FEVER VIRUS
<b>Specificity:</b>	YELLOW FEVER VIRUS
<b>Format:</b>	Ascites
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	2D12 (0G5)
<b>Isotype:</b>	IgG2a
<b>Quantity:</b>	0.1 ml

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
ELISA			▪	
Western Blotting			▪	
Immunofluorescence	▪			
Functional Assays	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

<b>Target Species</b>	Viral
<b>Product Form</b>	Ascites - Liquid
<b>Preservative Stabilisers</b>	None Present
<b>Immunogen</b>	17D strain of yellow fever virus

### Specificity

**Mouse anti Yellow fever virus antibody, clone 2D12** recognizes the envelope protein of the wild (Asibi) and vaccine strains of yellow fever virus. The clone has been reported to have neutralising activity against the Asibi strain ([Schlessinger et al. 1984](#)). No cross reactivity with other flaviviruses has been reported.

### References

- Schlesinger, J.J. *et al.* (1983) Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein. [Virology. 125 \(1\): 8-17.](#)
- Schlesinger, J.J. & Brandriss, M.W. (1983) 17D yellow fever virus infection of P388D1 cells mediated by monoclonal antibodies: properties of the macrophage Fc receptor. [J Gen Virol. 64 \(Pt 6\): 1255-62.](#)
- Schlesinger, J.J. *et al.* (1984) Analysis of 17D yellow fever virus envelope protein epitopes using

- monoclonal antibodies. [J Gen Virol. 65 \( Pt 10\): 1637-44.](#)
4. Gandini, M. *et al.* (2011) Dengue-2 and yellow fever 17DD viruses infect human dendritic cells, resulting in an induction of activation markers, cytokines and chemokines and secretion of different TNF- $\alpha$  and IFN- $\alpha$  profiles. [Mem Inst Oswaldo Cruz. 106 \(5\): 594-605.](#)
  5. Monath, T.P. *et al.* (1986) Sensitive and specific monoclonal immunoassay for detecting yellow fever virus in laboratory and clinical specimens. [J Clin Microbiol. 23 \(1\): 129-34.](#)
  6. Brandriss, M.W. *et al.* (1986) Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses. [J Gen Virol. 67 \( Pt 2\): 229-34.](#)
  7. Op De Beeck, A. *et al.* (2003) Role of the transmembrane domains of prM and E proteins in the formation of yellow fever virus envelope. [J Virol. 77 \(2\): 813-20.](#)
  8. Izurieta, R.O. *et al.* (2009) Anamnestic immune response to dengue and decreased severity of yellow fever. [J Glob Infect Dis. 1 \(2\): 111-6.](#)
  9. Thonnon, J. *et al.* (1998) Re-emergence of yellow fever in Senegal in 1995. [Am J Trop Med Hyg. 59 \(1\): 108-14.](#)
  10. Thonnon, J. *et al.* (1998) Yellow fever outbreak in Kaffrine, Senegal 1996: epidemiological and entomological findings. [Trop Med Int Health. 3 \(11\): 872-7.](#)
  11. Op De Beeck, A. *et al.* (2004) The transmembrane domains of the prM and E proteins of yellow fever virus are endoplasmic reticulum localization signals. [J Virol. 78 \(22\): 12591-602.](#)
  12. Ciczora, Y. *et al.* (2010) Identification of a dominant endoplasmic reticulum-retention signal in yellow fever virus pre-membrane protein. [J Gen Virol. 91 \(Pt 2\): 404-14.](#)
  13. Vratskikh, O. *et al.* (2013) Dissection of antibody specificities induced by yellow fever vaccination. [PLoS Pathog. 9 \(6\): e1003458.](#)

<b>Storage</b>	Store at -20°C only. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
<b>Shelf Life</b>	12 months from date of despatch.
<b>Health And Safety Information</b>	Material Safety Datasheet documentation #10194 available at: 10194: <a href="https://www.bio-rad-antibodies.com/uploads/MSDS/10194.pdf">https://www.bio-rad-antibodies.com/uploads/MSDS/10194.pdf</a>
<b>Regulatory</b>	For research purposes only

<b>North &amp; South America</b>	Tel: +1 800 265 7376 Fax: +1 919 878 3751 Email: <a href="mailto:antibody_sales_us@bio-rad.com">antibody_sales_us@bio-rad.com</a>	<b>Worldwide</b>	Tel: +44 (0)1865 852 700 Fax: +44 (0)1865 852 739 Email: <a href="mailto:antibody_sales_uk@bio-rad.com">antibody_sales_uk@bio-rad.com</a>	<b>Europe</b>	Tel: +49 (0) 89 8090 95 21 Fax: +49 (0) 89 8090 95 50 Email: <a href="mailto:antibody_sales_de@bio-rad.com">antibody_sales_de@bio-rad.com</a>
----------------------------------	---	------------------	---	---------------	---

'M269523:150413'

**Printed on 21 Jun 2018**